Corporate Information

7000 North Broadway

Building 3-307
Denver, CO 80221

Phone: (303) 863-8088
Fax: (303) 863-1218
www.accelr8.com

Recent News Releases

Accelr8 and Denver Health Notified by Department of Defense for Rapid Diagnostics Award

Tuesday, May 15, 2012

[Business Wire] - Accelr8 Technology Corporation and Denver Health received notice that the Defense Medical Research and Development Program recommended $2 million funding of a proposed 35-month...Read More

ACCELR8 TECHNOLOGY CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity S

Tuesday, Apr 24, 2012

Accelr8 Attracts Up To $35 Million Private Equity Investment

Monday, Apr 23, 2012

[Business Wire] - Accelr8 Technology Corporation announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of up to $35 million in Accelr8’s...Read More

Follow Me

Accelr8 Technology Corporation

Corporate Snapshot

Accelr8 Technology Corporation is developing an innovative system to analyze bacteria in life-threatening infections, with the objective of providing the physician with species identity, bacterial counts, and specific antibiotic resistance by direct bacterial extraction from patient specimens and direct single-cell analysis without culturing. Culturing requires many hours or days of bacterial growth in order to isolate bacterial strains and test them. The Company's BACcel rapid diagnostic system, in development, is the first technology demonstrated able to count and identify dangerous pathogens and their drug resistance expression within 6 hours of having a patient specimen, instead of 2-3 days required for culturing. As well, the Company has licensed its proprietary OptiChem bio-coatings to microarraying product manufacturers, providing continuing revenues from royalties. OptiChem has new opportunity in potential application to invasive medical devices, pharmaceutical packaging, and live-cell bioanalysis.